Finance

Beta
Lists
ABVX:NASDAQ
Abivax SA
$100.40
-1.24%
(-1.26) 1D
Jun 23, 1:18:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABVX...
Open
$101.71
High
$102.24
Low
$97.20
Mkt. cap
6.86B
Avg. vol.
2.39M
Volume
958.91K
52-wk high
$148.83
52-wk low
$6.20
Shares outstanding
79.78M
No. of employees
80
Open
$101.71
High
$102.24
Low
$97.20
Mkt. cap
6.86B
Avg. vol.
2.39M
Volume
958.91K
52-wk high
$148.83
52-wk low
$6.20
Shares outstanding
79.78M
No. of employees
80
News stories
From sources across the web
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated. The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees80
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com
Analyst Ratings
Based on 12 analysts giving stock ratings to ABVX in the past 3 months
Strong Buy
Buy
10
Hold
2
Sell
0
12 month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ABVX in the last 3 months.
Highest
Current $100.40
$187.00 (+86.25%)
Average
$143.17 (+42.60%)
Lowest
$90.00 (-10.36%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Gregory Renza
Truist Financial
Buy
Maintained
$135.00
+34.5%
06/22/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$170.00
+69.3%
06/16/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$165.00
+64.3%
06/16/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$175.00
+74.3%
06/15/2026
Julian Harrison
BTIG
Buy
Maintained
$150.00
+49.4%
06/15/2026
Etzer Darout
Barclays
Buy
Maintained
$148.00
+47.4%
06/16/2026
Andy Chen
Wolfe Research
Buy
Reiterated
$136.00
+35.5%
06/03/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$140.00
+39.4%
06/02/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$132.00
+31.5%
06/02/2026
David Nierengarten
Wedbush
Hold
Upgraded
$90.00
-10.4%
06/02/2026
Faisal Khurshid
Jefferies
Hold
Downgraded
$90.00
-10.4%
06/01/2026
Jason Butler
Citizens JMP
Buy
Maintained
$187.00
+86.3%
06/02/2026
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.05M
639.00K
1.91M
1.34M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
38.64M
55.42M
44.40M
49.54M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.94M
27.34M
27.69M
8.03M
Operating expense
47.54M
81.35M
73.56M
57.57M
Total operating expenses
47.54M
81.35M
73.56M
57.57M
Operating income
-46.50M
-80.71M
-71.65M
-56.23M
Other non operating income
2.66M
-74.20M
-4.96M
119.00K
EBT including unusual items
-48.41M
-153.36M
-76.11M
-48.24M
EBT excluding unusual items
-48.41M
-153.36M
-80.84M
-51.51M
Income tax expense
-
-
5.85M
228.00K
Effective tax rate
-
-
-7.68%
-0.47%
Other operating expenses
-46.00K
-1.40M
1.47M
-
Net income
-48.41M
-153.36M
-81.96M
-48.47M
Net profit margin
-4,624.07%
-23,999.69%
-4,282.13%
-3,606.25%
Earnings per share
-
-
-
-
Interest and investment income
190.00K
3.36M
1.19M
644.00K
Interest expense
-3.52M
-4.21M
-15.27M
-2.54M
Net interest expenses
-3.33M
-852.00K
-14.08M
-1.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
-46.47M
-80.63M
-70.76M
-56.14M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer